Sigal Kaplan, PhD, B.Pharm

Director, Pharmacoepidemiology Leader
Teva Pharmaceutical Industries Ltd., Israel

Poster(s):

• (B-051) Evaluation of the effectiveness of pregnancy prevention programme (PPP) for oral retinoids (acitretin, alitretinoin, and isotretinoin): a European before-after drug utilisation study (DUS) using secondary data
  Monday, August 25, 2025

  11:30 AM - 1:00 PM ET